The fact that GoF ADAMTS‐13 was effective at lower doses than WT ADAMTS‐13 most likely reflects the enhanced activity of the preactivated ADAMTS‐13 variant, which could become useful in the setting of stroke. This evidence concerns the gene ADAMTS13 and stroke disorder.